[Clinical study of phacoemulsification with NeoSoniX handpiece]

To evaluate the outcomes of phacoemulsification with NeoSoniX handpiece.

It was a prospective random controlled clinical trial. Six hundred and fifty-nine cases (659 eyes) having phacoemulsification were prospectively comprised in this study. All cases were divided into two groups randomly. Group 1(NeoSoniX handpiece) include 317 cases. Group 2 (standard handpiece) include 342 cases. Preoperative measurements included best correct visual acuity (BCVA) and cataract grade according to the Emery classification. Intraoperative measurements included active power (AP) and effective phaco time (EPT). Postoperative measurements included BCVA and corneal edema.

Grade I to III nuclear sclerosis, the AP was 3.53% +/- 1.76% with NeoSoniX and 3.84% +/- 1.93 % with standard handpiece, the EPT was (0.23 +/- 0.15) minutes and (0.25 +/- 0.19) minutes, respectively. There was no significant difference in the postoperative BCVA and cornea edema between the two groups. Grade IV or V nuclear sclerosis, the AP was 6.31% +/- 2.78 % with NeoSoniX and 9.45% +/- 4.17 % with standard handpiece, the EPT was (0.55 +/- 0.28) minutes and (0.83 +/- 0.44) minutes, respectively. There was significant difference in the postoperative 1 day BCVA and cornea edema between the two groups. There was significant difference in the postoperative 7 days BCVA and cornea edema between the two groups.

Ultrasound energy consumption with NeoSoniX was significantly less than with US alone in emulsifying cataracts of optimum density and dense hard cataracts.